Resch, Bernhard <br/><br/>
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.  [electronic resource] 

 -  The Pediatric infectious disease journal  Jan 2012 
 - e1-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-0987 
<br/><br/><label>Standard No.: </label>10.1097/INF.0b013e318235455b  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized--economics<br/>Austria--epidemiology<br/>Chemoprevention<br/>Cost-Benefit Analysis<br/>Decision Trees<br/>Female<br/>Hospitalization<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Infant, Premature<br/>Infant, Premature, Diseases--epidemiology<br/>Male<br/>Palivizumab<br/>Respiratory Syncytial Virus Infections--epidemiology<br/>Respiratory Syncytial Viruses--drug effects<br/>Respiratory Tract Infections--epidemiology<br/>Risk<br/>Treatment Outcome